The effectiveness of atorvastatin for deep vein thrombosis prevention in cancer patients undergoing chemotherapy

INTERVENTION: Participants who meet the inclusion criteria will be randomized with simple randomization into the study group (atorvastatin 20 mg daily orally) or the control group (rivaroxaban 10 mg daily orally) for 3 months. At baseline Doppler ultrasonography is performed on the lower extremities; IL‐6, CRP, TF, F1+2, D‐dimer, NF‐kB and TNF‐alpha serum levels are measured and re‐measured after 3 months. CONDITION: Prevention of deep vein thrombosis in cancer patients who have high risk of thrombosis while undergoing chemotherapy ; Circulatory System PRIMARY OUTCOME: Deep vein thrombosis event measured using Doppler ultrasonography at baseline and 3 months SECONDARY OUTCOME: ; 1. IL‐6 is measured using ELISA at baseline and 3 months; 2. NF‐kB is measured using ELISA at baseline and 3 months; 3. CRP is measured using a spectrophotometer at baseline and 3 months; 4. TF is measured using ELISA at baseline and 3 months; 5. F1+2 is measured using ELISA at baseline and 3 months; 6. D‐dimer is measured using ELISA at baseline and 3 months; 7. TNF‐alpha is measured using ELISA at baseline and 3 months; 8. Cost effectiveness is measured using the total cost for each subject; INCLUSION CRITERIA: 1. Cancer patient with a definite diagnosis of cancer based on anatomy pathological examination 2. Cancer patients who have not received any chemotherapy 3. Khorana risk score =2 4. Age 18‐60 years old 5. Has signed the participant agreement